The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Biologics and Biosimilars-Global Market Insights and Sales Trends 2025

Biologics and Biosimilars-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1817511

No of Pages : 120

Ask Your Query

Synopsis

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

The global Biologics and Biosimilars market size is expected to reach US$ 674510 million by 2029, growing at a CAGR of 8.7% from 2023 to 2029. The market is mainly driven by the significant applications of Biologics and Biosimilars in various end use industries. The expanding demands from the Hospital, Retail Pharmacy and Other, are propelling Biologics and Biosimilars market. Monoclonal Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Interferon segment is estimated at % CAGR for the next seven-year period.

Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Biologics and Biosimilars market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Biologics and Biosimilars market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biologics and Biosimilars sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Biologics and Biosimilars covered in this report include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc.

The global Biologics and Biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • Roche
  • Amgen
  • AbbVie
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • Biogen
  • Celltrion
  • Sobi
  • 3SBIO
  • Changchun High Tech
  • Kanghong Pharma
  • Innovent Biologics
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory

Global Biologics and Biosimilars market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Biologics and Biosimilars market, Segment by Type:

  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Others

Global Biologics and Biosimilars market, by Application

  • Hospital
  • Retail Pharmacy
  • Other

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biologics and Biosimilars companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index

1 Market Overview of Biologics and Biosimilars
1.1 Biologics and Biosimilars Market Overview
1.1.1 Biologics and Biosimilars Product Scope
1.1.2 Biologics and Biosimilars Market Status and Outlook
1.2 Global Biologics and Biosimilars Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biologics and Biosimilars Market Size by Region (2018-2029)
1.4 Global Biologics and Biosimilars Historic Market Size by Region (2018-2023)
1.5 Global Biologics and Biosimilars Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biologics and Biosimilars Market Size (2018-2029)
1.6.1 North America Biologics and Biosimilars Market Size (2018-2029)
1.6.2 Europe Biologics and Biosimilars Market Size (2018-2029)
1.6.3 Asia-Pacific Biologics and Biosimilars Market Size (2018-2029)
1.6.4 Latin America Biologics and Biosimilars Market Size (2018-2029)
1.6.5 Middle East & Africa Biologics and Biosimilars Market Size (2018-2029)
2 Biologics and Biosimilars Market by Type
2.1 Introduction
2.1.1 Monoclonal Antibodies
2.1.2 Interferon
2.1.3 Insulin
2.1.4 Vaccines
2.1.5 Others
2.2 Global Biologics and Biosimilars Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biologics and Biosimilars Historic Market Size by Type (2018-2023)
2.2.2 Global Biologics and Biosimilars Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biologics and Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biologics and Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biologics and Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biologics and Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biologics and Biosimilars Revenue Breakdown by Type (2018-2029)
3 Biologics and Biosimilars Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Retail Pharmacy
3.1.3 Other
3.2 Global Biologics and Biosimilars Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biologics and Biosimilars Historic Market Size by Application (2018-2023)
3.2.2 Global Biologics and Biosimilars Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biologics and Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biologics and Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biologics and Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biologics and Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biologics and Biosimilars Revenue Breakdown by Application (2018-2029)
4 Biologics and Biosimilars Competition Analysis by Players
4.1 Global Biologics and Biosimilars Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biologics and Biosimilars as of 2022)
4.3 Date of Key Players Enter into Biologics and Biosimilars Market
4.4 Global Top Players Biologics and Biosimilars Headquarters and Area Served
4.5 Key Players Biologics and Biosimilars Product Solution and Service
4.6 Competitive Status
4.6.1 Biologics and Biosimilars Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Biologics and Biosimilars Products, Services and Solutions
5.1.4 Roche Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Biologics and Biosimilars Products, Services and Solutions
5.2.4 Amgen Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 AbbVie
5.3.1 AbbVie Profile
5.3.2 AbbVie Main Business
5.3.3 AbbVie Biologics and Biosimilars Products, Services and Solutions
5.3.4 AbbVie Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Biologics and Biosimilars Products, Services and Solutions
5.4.4 Sanofi Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Biologics and Biosimilars Products, Services and Solutions
5.5.4 Johnson & Johnson Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Biologics and Biosimilars Products, Services and Solutions
5.6.4 Pfizer Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Novo Nordisk
5.7.1 Novo Nordisk Profile
5.7.2 Novo Nordisk Main Business
5.7.3 Novo Nordisk Biologics and Biosimilars Products, Services and Solutions
5.7.4 Novo Nordisk Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.7.5 Novo Nordisk Recent Developments
5.8 Eli Lilly
5.8.1 Eli Lilly Profile
5.8.2 Eli Lilly Main Business
5.8.3 Eli Lilly Biologics and Biosimilars Products, Services and Solutions
5.8.4 Eli Lilly Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.8.5 Eli Lilly Recent Developments
5.9 Novartis
5.9.1 Novartis Profile
5.9.2 Novartis Main Business
5.9.3 Novartis Biologics and Biosimilars Products, Services and Solutions
5.9.4 Novartis Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.9.5 Novartis Recent Developments
5.10 Merck
5.10.1 Merck Profile
5.10.2 Merck Main Business
5.10.3 Merck Biologics and Biosimilars Products, Services and Solutions
5.10.4 Merck Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.10.5 Merck Recent Developments
5.11 Biogen
5.11.1 Biogen Profile
5.11.2 Biogen Main Business
5.11.3 Biogen Biologics and Biosimilars Products, Services and Solutions
5.11.4 Biogen Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.11.5 Biogen Recent Developments
5.12 Celltrion
5.12.1 Celltrion Profile
5.12.2 Celltrion Main Business
5.12.3 Celltrion Biologics and Biosimilars Products, Services and Solutions
5.12.4 Celltrion Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.12.5 Celltrion Recent Developments
5.13 Sobi
5.13.1 Sobi Profile
5.13.2 Sobi Main Business
5.13.3 Sobi Biologics and Biosimilars Products, Services and Solutions
5.13.4 Sobi Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.13.5 Sobi Recent Developments
5.14 3SBIO
5.14.1 3SBIO Profile
5.14.2 3SBIO Main Business
5.14.3 3SBIO Biologics and Biosimilars Products, Services and Solutions
5.14.4 3SBIO Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.14.5 3SBIO Recent Developments
5.15 Changchun High Tech
5.15.1 Changchun High Tech Profile
5.15.2 Changchun High Tech Main Business
5.15.3 Changchun High Tech Biologics and Biosimilars Products, Services and Solutions
5.15.4 Changchun High Tech Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.15.5 Changchun High Tech Recent Developments
5.16 Kanghong Pharma
5.16.1 Kanghong Pharma Profile
5.16.2 Kanghong Pharma Main Business
5.16.3 Kanghong Pharma Biologics and Biosimilars Products, Services and Solutions
5.16.4 Kanghong Pharma Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.16.5 Kanghong Pharma Recent Developments
5.17 Innovent Biologics
5.17.1 Innovent Biologics Profile
5.17.2 Innovent Biologics Main Business
5.17.3 Innovent Biologics Biologics and Biosimilars Products, Services and Solutions
5.17.4 Innovent Biologics Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.17.5 Innovent Biologics Recent Developments
5.18 Gan&Lee
5.18.1 Gan&Lee Profile
5.18.2 Gan&Lee Main Business
5.18.3 Gan&Lee Biologics and Biosimilars Products, Services and Solutions
5.18.4 Gan&Lee Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.18.5 Gan&Lee Recent Developments
5.19 Tonghua Dongbao
5.19.1 Tonghua Dongbao Profile
5.19.2 Tonghua Dongbao Main Business
5.19.3 Tonghua Dongbao Biologics and Biosimilars Products, Services and Solutions
5.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.19.5 Tonghua Dongbao Recent Developments
5.20 United Laboratory
5.20.1 United Laboratory Profile
5.20.2 United Laboratory Main Business
5.20.3 United Laboratory Biologics and Biosimilars Products, Services and Solutions
5.20.4 United Laboratory Biologics and Biosimilars Revenue (US$ Million) & (2018-2023)
5.20.5 United Laboratory Recent Developments
6 North America
6.1 North America Biologics and Biosimilars Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Biologics and Biosimilars Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biologics and Biosimilars Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biologics and Biosimilars Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biologics and Biosimilars Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biologics and Biosimilars Market Dynamics
11.1 Biologics and Biosimilars Industry Trends
11.2 Biologics and Biosimilars Market Drivers
11.3 Biologics and Biosimilars Market Challenges
11.4 Biologics and Biosimilars Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock